

Lupin Pharmaceuticals, Inc

[View the current Lupin Pharmaceuticals, Inc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/25878-Lupin+Pharmaceuticals%2C+Inc.html)

(<http://www.bioportfolio.com/biocorporate/25878-Lupin+Pharmaceuticals%2C+Inc.html>)

Contact Details:

**Harborplace Tower111 South Calvert Street 21st
floor
Baltimore
Maryland
21202
United States of America**

Tel: 1-410 576 2000

Fax: 1-410 576 2221

Email: ussales@lupinworld.com

Lupin is one of the world's largest manufacturers of drugs that combat tuberculosis, bacterial infections, and cardiovascular disease. Our portfolio of drugs, manufactured in global-scale USFDA and UKMCA approved plants, also includes NSAIDS, Cox2 inhibitors and herbal-based phytomedicines.

Press Releases on Lupin Pharmaceuticals, Inc:

<p>Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients</p>	<p>23rd November, 2009</p>	<p>Cumberland Pharmaceuticals Inc.</p>	<p>NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of</p>
<p>Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009</p>	<p>23rd November, 2009</p>	<p>Lexicon Pharmaceuticals, Inc.</p>	<p>THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXXR), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with</p>

[Isis Pharmaceuticals \(Nasdaq: ISIS\) Letter to Shareholders](#)

23rd November, 2009

Isis Pharmaceuticals, Inc.

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the

[Oceanside Pharmaceuticals Announces Launch of Librax\(R\) AG](#)

23rd November, 2009

Valeant Pharmaceuticals International

ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide

[Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference](#)

23rd November, 2009

Sagent Pharmaceuticals, Inc.

SCHAUMBURG, Ill., Nov. 23 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon,

BioNews Results for Lupin Pharmaceuticals, Inc



- [Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA](#)
Genetic Engineering News: Nov 10 2009 3:18PM Matching: lupin pharmaceuticals inc
- [Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA](#)
Pharmacy Choice: Nov 10 2009 10:59PM Matching: lupin pharmaceuticals inc
- [Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA](#)
Yahoo! Canada: Nov 10 2009 8:28PM Matching: lupin pharmaceuticals inc
- [Sun Pharma loses patent battle against Forest Labs on Alzheimer's drug](#)
PharmaBiz: Oct 23 2009 3:14AM Matching: lupin pharmaceuticals inc
- [Medicines Co. sues Teva over Angiomax](#)
Haaretz: Oct 12 2009 1:54AM Matching: lupin pharmaceuticals inc

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

